Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...
Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano and Chief Development Officer Judith Klimovsky will participate in a fireside chat at the 45th Annual TD Cowen ...
Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $31.00. The ...
Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...
Research analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for shares of Genmab A/S in a report issued on Thursday, February 13th. Leerink Partnrs analyst J. Chang forecasts that the ...
Leerink Partnrs upgraded shares of Genmab A/S (NASDAQ:GMAB – Free Report) from a hold rating to a strong-buy rating in a ...
Genmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes ...
7d
Fintel on MSNLeerink Partners Upgrades Genmab A (GMAB)Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market ...
Exane analyst Victor Floch upgraded Genmab (NASDAQ:GMAB) A/S shares from Underperform to Neutral, adjusting the price target ...
We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results